# "Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX)

> **NCT01855971** · PHASE2 · COMPLETED · sponsor: **Parc de Salut Mar** · enrollment: 44 (actual)

## Conditions studied

- Fragile X Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** EGCG
- **DIETARY_SUPPLEMENT:** Placebo
- **OTHER:** Cognitive training

## Key facts

- **NCT ID:** NCT01855971
- **Lead sponsor:** Parc de Salut Mar
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06-11
- **Primary completion:** 2015-07-31
- **Final completion:** 2015-10-31
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2019-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01855971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01855971, ""Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01855971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*